2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.01: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing: Results from Latin America

PP01.01: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing: Results from Latin America

Back to course

Pdf Summary

The 2024 International Association for the Study of Lung Cancer (IASLC) survey focused on biomarker testing in Latin America reveals significant barriers and gaps in optimal implementation compared to other global regions. While 98% of Latin American respondents agree on the importance of biomarker testing in influencing outcomes, only 69% and 33% prioritize its importance for late- and early-stage lung cancer, respectively. Key barriers include cost, sample quality, access, awareness, and long results turnaround times.<br /><br />Respondents identified several solutions to these challenges, advocating for implementing standardized testing protocols, government-level interventions, addressing cost and reimbursement issues, increasing awareness and education, enhancing administrative and organizational support, and improving access and availability.<br /><br />The importance disparity is evident as only 54% of respondents treat patients before biomarker test results are available, and 78% express dissatisfaction with current testing conditions in their countries. The survey gathered 145 responses across 16 Latin American countries, illuminating a stark contrast in testing practices compared to global standards.<br /><br />The persistent barriers outlined align with earlier global findings from 2018, emphasizing continued challenges in cost, sample quality, and awareness. The IASLC, based on these findings, plans to launch initiatives aimed at improving biomarker testing practices in the region.<br /><br />The survey results reinforce the necessity for a paradigm shift globally, acknowledging biomarker testing's impact on lung cancer treatment outcomes and the urgency to address the highlighted barriers systematically through collaborative efforts among medical, governmental, and advocacy stakeholders.

Asset Subtitle

Matthew Smeltzer

Keywords

IASLC

biomarker testing

lung cancer

Latin America

barriers

standardized protocols

government interventions

awareness

cost issues

global standards